Induction therapy-3 cycles of BvC (Brentuximab vedotin plus Chidamide)
2024470
Unknown small_molecule active
Quick answer
Induction therapy-3 cycles of BvC (Brentuximab vedotin plus Chidamide) for CD30+ Peripheral T-cell Lymphoma is a Unknown program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- CD30+ Peripheral T-cell Lymphoma
- Phase
- Unknown
- Modality
- small_molecule
- Status
- active